Sunday Prep 9/12 - $ABUS Higher The Better! The higher the better on this name, but will be stalking it for lower highs and an area to get short with defined risk.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.38 USD
−69.92 M USD
6.17 M USD
148.63 M
About Arbutus Biopharma Corporation
Sector
Industry
CEO
Lindsay Androski
Website
Headquarters
Warminster
Founded
2005
FIGI
BBG000RR8V85
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of ABUS is 3.23 USD — it has decreased by −2.12% in the past 24 hours. Watch Arbutus Biopharma Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arbutus Biopharma Corporation stocks are traded under the ticker ABUS.
ABUS stock has fallen by −10.77% compared to the previous week, the month change is a 13.33% rise, over the last year Arbutus Biopharma Corporation has showed a 12.94% increase.
We've gathered analysts' opinions on Arbutus Biopharma Corporation future price: according to them, ABUS price has a max estimate of 7.00 USD and a min estimate of 4.00 USD. Watch ABUS chart and read a more detailed Arbutus Biopharma Corporation stock forecast: see what analysts think of Arbutus Biopharma Corporation and suggest that you do with its stocks.
ABUS reached its all-time high on Mar 13, 2014 with the price of 31.48 USD, and its all-time low was 0.82 USD and was reached on Oct 21, 2019. View more price dynamics on ABUS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABUS stock is 4.50% volatile and has beta coefficient of 0.12. Track Arbutus Biopharma Corporation stock price on the chart and check out the list of the most volatile stocks — is Arbutus Biopharma Corporation there?
Today Arbutus Biopharma Corporation has the market capitalization of 618.48 M, it has increased by 2.93% over the last week.
Yes, you can track Arbutus Biopharma Corporation financials in yearly and quarterly reports right on TradingView.
Arbutus Biopharma Corporation is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
ABUS earnings for the last quarter are −0.07 USD per share, whereas the estimation was −0.08 USD resulting in a 12.50% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about Arbutus Biopharma Corporation earnings.
Arbutus Biopharma Corporation revenue for the last quarter amounts to 1.57 M USD, despite the estimated figure of 1.56 M USD. In the next quarter, revenue is expected to reach 1.59 M USD.
ABUS net income for the last quarter is −12.53 M USD, while the quarter before that showed −19.72 M USD of net income which accounts for 36.44% change. Track more Arbutus Biopharma Corporation financial stats to get the full picture.
No, ABUS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 12, 2025, the company has 44 employees. See our rating of the largest employees — is Arbutus Biopharma Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arbutus Biopharma Corporation EBITDA is −68.59 M USD, and current EBITDA margin is −1.11 K%. See more stats in Arbutus Biopharma Corporation financial statements.
Like other stocks, ABUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arbutus Biopharma Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arbutus Biopharma Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arbutus Biopharma Corporation stock shows the neutral signal. See more of Arbutus Biopharma Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.